HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch

Executive Summary

Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.

You may also be interested in...



Sanofi Secures First EU Market Approval for OTC Cialis

Following an application through the decentralised procedure, Ireland is the first EU member state to approve Sanofi's Cialis (tadalafil) for non-prescription sale. An OTC version of the blockbuster erectile dysfunction treatment has also been given the green light in Norway, but Germany has rejected the product.

Viatris Puts OTC Business Up For Sale

Viatris has decided to exit the consumer health market and has put up for sale an OTC business which is thought to generate around $1.0bn in annual sales.

Why Did Germany Reject Sildenafil OTC Switch?

Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel